 |
|
|
Important Notice: The Alzheimer Research Forum does not
provide medical advice nor promote any product or service. The contents are for
informational purposes only and are not intended to substitute for professional
medical advice, diagnosis or treatment. Always seek advice from a qualified physician
or health care professional about any medical concern, and do not disregard professional
medical advice because of anything you may read on this web site. The views of individuals
quoted on this site are not necessarily those of the Alzheimer Research Forum.
|
RESULTS
(listed alphabetically):
|
|
NAME:
Flurizan™
|
|
OTHER NAMES:
MPC-7869, r-flurbiprofen, tarenflurbil
|
|
FDA PHASE:
Discontinued
|
|
MECHANISMS:
Selective amyloid-lowering agent (SALA). Flurizan lowers levels of Aβ42, a major constituent of plaques and a key pathogenic agent of Alzheimer disease.
|
|
ROLE IN ALZHEIMER'S DISEASE:
Selectively lowers production of toxic amyloid (Aβ42)
and thus inhibits the cascade of amyloid accumulation,
plaque formation, and neurodegeneration that are the
hallmarks of dementia. Early intervention, and targeting
the initial stage of the disease process, offers the
potential for a therapy with disease modification
properties. In mouse models, Flurizan™ reduced insoluble
amyloid in the brain and improved spatial reference
learning and memory.
|
|
|
|
|
|
|
Home
